|Videos|October 3, 2020

HER2-targeted Therapy: Routes of Administration

Author(s)Staff

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.


Latest CME